| | 52-Week Phase 3 Study Found Investigational Drug Dapagliflozin Plus Metformin Similar to Glipizide Plus Metformin in Improving Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus | | | AstraZeneca and Bristol-Myers Squibb Company today announced results from a randomised, double-blind Phase 3 clinical study in adults with type 2 diabetes inadequately controlled on metformin therapy alone. | |  View full press release | | | This email has been sent via AstraZeneca's email alert service. Update your email preferences, unsubscribe from this service or contact us. | | | |
No comments:
Post a Comment